

Table of Contents

<i>Foreword</i>	v
<i>Acknowledgements</i>	vii
<i>Table of Cases</i>	xiii
<i>Table of Instruments and Legislation</i>	xv
1. Context, Approach and Overview.....	1
I. Introduction.....	1
A. Starting Points	2
B. Research Agenda and Aims.....	3
C. Key Arguments and Next Steps	6
II. Law, Public Health and Participation	9
A. Law and Public Health: A Very Brief Overview	9
B. Citizen Participation	15
C. Taking Citizen Participation Seriously.....	19
III. Governing in Late Modernity: Theory, Concepts and Methods	20
A. Technologies of Governing: Risk, Freedom/Security and Governmentality	20
B. Regulating Risk.....	22
C. Neoliberalism	26
D. Biopolitics and ‘The Governed’ as Citizens.....	28
IV. Overview.....	30
Part I: Governing Public Health	
2. EU Public Health Governance: From the Overarching Architecture to the Health Strategy	37
I. Introduction.....	37
II. The EU and Public Health: Legal Competence, Governance and Responsibility.....	38
A. Legal Competence	38
B. The Overarching Architecture and Programmatic Priorities of EU Governance.....	44
III. Operationalising the Overarching Strategy in the Field of Public Health: <i>Together for Health</i>	48
A. The Market-Oriented Rationale	49
B. Overview of Principles and Objectives	51
C. Health in All Policies (HIAP)	54
i. Technologies of Knowledge-based Policy-making: Impact Assessment	56

x *Table of Contents*

ii. Technologies of Agency and Performance: Monitoring, Measuring and Evaluating	63
D. The EU as a Security Actor and the Production of Legitimacy	68
IV. Structured Cooperation: Public Health Policy Implementation and the Health Programmes	70
A. Structured Cooperation	70
B. EU Health Programmes: Steering Through Funding.....	72
V. Conclusion	76
3. Cancer.....	78
I. Introduction.....	78
II. From the Overarching Architecture of Governance to <i>Action Against Cancer: European Partnership via Together for Health</i>	79
III. European Partnership for Action Against Cancer.....	83
A. Overview of Rationale and Objectives	83
B. Areas and Actions for a ‘Comprehensive Policy Response’	87
i. The Most Cost-effective Response	87
ii. Bolstering Technologies of Knowledge-based Policy: Identification and Dissemination of Good Practice.....	90
iii. Cooperation and Coordination in Cancer Research as a Technology of Knowledge Production.....	92
iv. Facilitating Technologies of Agency and Performance: The Benchmarking Process.....	97
C. The Partnership Approach as Steering.....	98
i. Broad Overview.....	98
ii. Work Packages.....	100
iii. Extending and Deepening Governance: National Cancer Plans.....	106
IV. Conclusion	107
4. HIV/AIDS.....	109
I. Introduction.....	109
II. From the Overarching Architecture of Governance to <i>Combating HIV/AIDS within the EU and in the Neighbouring Countries—Reflecting Together for Health</i>	110
III. Taking Action: <i>Combating HIV/AIDS within the EU and in the Neighbouring Countries</i>	115
A. Mapping ‘HIV in Europe’: Constituting a Problem for EU Governance.....	115
B. Key Contours of the EU’s Governance.....	120
i. Distributed Responsibilities.....	120
ii. The Centrality of Prevention	125
iii. Most ‘At Risk’ Regions and Groups	126

Table of Contents xi

IV.	Technologies for the Gathering and Production of Knowledge.....	133
A.	Surveillance.....	133
B.	Pharmaceuticals and Other Medical and Technological Responses.....	138
V.	Conclusion	141
5.	Pandemics and Beyond.....	144
I.	Introduction.....	144
II.	From the Overarching Architecture of Governance to <i>Pandemic Influenza Preparedness—Reflecting Together for Health</i>	146
III.	Governing the Future Through Preparedness Planning.....	151
A.	Ensuring Preparedness Through Coordination Based on Knowledge of Member States' Plans	151
B.	Risk Assessment and Management.....	154
i.	Risk Assessment and Further Technologies for the Gathering and Production of Knowledge.....	154
ii.	Risk Management—And the Importance of Medical Countermeasures and Pharmaceutical Fixes	158
C.	Communication	162
IV.	Conclusion	164
Part II: Enhancing Citizen Participation in Governing Public Health		
6.	Citizen Participation in Governing: Discursive Resources, Tools and Spaces.....	169
I.	Introduction.....	169
II.	Summary of the Findings So Far	170
A.	The Centrality of Risk	170
B.	Neoliberal Underpinnings as the Structuring Themes of the Policy Domain	174
III.	Risk, Public Health and Citizen Participation	177
IV.	Opening Discursive Space and Powering Technologies of Participation	186
A.	Openings and Possibilities for Citizen Participation.....	186
B.	Resources for Participation: Human Rights, Bioethics and (Supra-)Stewardship Responsibility	190
i.	Human Right and Bioethics	190
ii.	(Supra-)Stewardship Responsibility.....	195
iii.	Towards Participation	198
V.	Conclusion	199
7.	Querying Framing and Knowledge Production: Risk, Numbers, Measurement and Evaluation	201
I.	Introduction.....	201
II.	Querying Risk	202

xii *Table of Contents*

A. Framing, Knowledge and Responses	202
B. Skewing Attention and Resources Towards Consequences	205
III. Querying Scientific and Technical Knowledge Production	209
A. Looking More Closely at Knowledge Production.....	209
B. Steering Governance Through Indicators.....	212
i. Instruments of Governance.....	212
ii. Salient Features.....	215
iii. Demanding Alternatives	217
IV. Clinical Trials.....	220
A. Producing Data in Support of Magic Bullet Responses and Pharmaceutical Fixes	220
B. Situating Clinical Trials in EU Governance	222
C. Informed Consent.....	226
D. Designing Clinical Trials	230
E. Using Placebos in Clinical Trials Abroad	233
F. Clinical Trials Abroad and the European and Developing Countries Clinical Trials Partnership.....	237
G. Contesting Regulatory Design and Demanding Redesign	239
V. Conclusion	240
8. Querying Interventions: Magic Bullet Responses and Technological Fixes	242
I. Introduction.....	242
II. Interventions	244
A. General Reflections on Vulnerability.....	244
i. A Brief Note on Surveillance	244
ii. Wider Interventions and the Hierarchy of Public Health Problems	246
iii. Framing, Responsibility and Accountability.....	254
B. Pharmaceuticalisation and Vulnerability	255
III. Pharmaceuticals Abroad: Access, Prioritisation and Triage.....	257
A. Access	257
i. Combating Barriers and the Importance of EU Trade Policy.....	257
ii. Patents as Barriers to Access	260
iii. Alternative Mechanisms.....	264
B. Prioritisation and Triage	265
i. The View ‘On the Ground’.....	265
ii. Triage, Valuing and Access	268
IV. Conclusion	270
9. Conclusion	273
<i>Select Bibliography</i>	278
<i>Index</i>	284